PEP-CTN EHR to RAVE supplement

PEP-CTN EHR 至 RAVE 补充

• 批准号: 10440223
• 负责人: Brenda J. Weigel
• 金额: $ 63.85万
• 依托单位: PUBLIC HEALTH INSTITUTE
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-09-20 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10440223
• 关键词: Adolescent; Australia; Biological; Biology; Canada; Characteristics; Child; Childhood; Clinical Research; Clinical Trials; Clinical Trials Network; Cohort Studies; Common Terminology Criteria for Adverse Events; Complex; Data; Data Collection; Data Security; Data Set; Data Storage and Retrieval; Databases; Development; Drug Kinetics; Enrollment; Ensure; Environment; Future; Genes; Genomics; Individual; Informatics; Infrastructure; Institution; International; Laboratories; Laboratory Research; Laboratory Study; Malignant Childhood Neoplasm; Malignant Neoplasms; Maps; Medidata; Mission; Modeling; New Agents; Parents; Patients; Pediatric Oncology; Pediatric Oncology Group; Peer Review; Pharmacogenetics; Pharmacology; Pharmacology Study; Phase; Pilot Projects; Process; Protocols documentation; Reporting; Research; Resources; Role; Signal Transduction; Site; System; Testing; Therapeutic; TimeLine; Update; cancer therapy; data exchange; early phase clinical trial; exome sequencing; imaging modality; imaging study; member; novel anticancer drug; operation; pilot trial; response; skills; systems research; targeted agent; targeted treatment; tool; transcriptome sequencing; tumor; tumor DNA

PEP-CTN Project Summary/Abstract: The mission of the Pediatric Early Phase Clinical Trials Network (PEP-CTN) is to identify and develop effective new agents for children and adolescents with cancer, through rational and efficient clinical and laboratory research. PEP-CTN clinical trials will incorporate correlative genomics, biology, pharmacology, and imaging studies to further the understanding of the disposition and action of new agents introduced into the treatment of children with cancer. Annually, the PEP-CTN will enroll approximately 120 children and adolescents with cancer onto clinical trials of novel anticancer agents at the 21 core-member sites and 21 non-core member sites throughout the US, Canada, and Australia. The network institutions are selected through a peer review process, and serve as a national and international model for new agent development in pediatric oncology. The PEP-CTN leverages the database infrastructure and resources of the parent Children’s Oncology Group while maintaining its own administrative and operational infrastructure to ensure rapid development, implementation, and reporting of specialized and complex early phase clinical trials. The PEP-CTN has expertise and resources for the conduct of translational biology, pharmacokinetic, and pharmacogenetic studies, and utilizes state-of-the-art informatics systems to facilitate the transfer of response and correlative imaging studies for central review and analyses. The PEP-CTN's primary specific aims are: 1) To safely and efficiently introduce novel anticancer agents into the pediatric setting through the conduct of early phase clinical trials; 2) To expeditiously obtain preliminary efficacy signals through use of phase 2 expansion cohorts and pilot studies in order to inform tumor specific trials that will be conducted across COG sites; 3) To perform genomic analyses, including single gene studies or gene panels, to identify appropriate patients for early phase studies of targeted agents; 4) To identify associations of tumor characteristics with response to new agents using genomic analyses such as whole exome sequencing and RNA sequencing; 5) To incorporate pharmacologic and biologic endpoints, including circulating tumor DNA, other translational laboratory studies, and imaging modalities, into early phase studies, in order to enhance our understanding of the new agents and their effect on tumors.. Development of targeted therapy for childhood cancer is a high priority as it offers the prospect of more efficacious and less toxic therapeutics.

PEP-CTN项目概述/摘要：